The cytokine stem cell factor (SCF) synergizes with IL-7 to enhance the proliferation of thymocytes. We therefore investigated the role of the SCF receptor, the protooncogene c-kit, in the pathogenesis of pediatric T-lineage malignancies. 
Introduction
Bone marrow lymphocyte precursors are frequent targets of malignant transformation. The heterogeneous groups of nonHodgkin's lymphoma and acute lymphoblastic leukemia can be considered the malignant counterparts of different stages of B and T cell differentiation. These malignant cells originate from lineage-committed hematopoietic progenitor cells and from thymocytes which express different markers including the product of the c-kit protooncogene. This protooncogene encodes the specific surface receptor for the pluripotent hematopoietic colony-stimulating factor SCF.
1-3 SCF acts synergistically with other growth factors, including erythropoietin (EPO), G-CSF, macrophage (M)-CSF, GM-CSF, IL-3, IL-6, IL-11 and IL-12, [4] [5] [6] [7] and plays an important role in normal and leukemic hematopoiesis. Mature lymphocytes exhibit little or no responsiveness to the c-kit ligand, SCF. 1 In malignant hematopoietic cells, c-kit is expressed by cells of the erythroid, megakaryocytic and mast cell lineages. 1 It is also expressed in most cases of acute myeloblastic leukemia (AML) 8 and in some cases of chronic myelogenous leukemia (CML) in blast crisis. By contrast, little or no expression of c-kit has been observed in human leukemia cell lines of the lymphoid lineage [9] [10] [11] and in blast cells of acute lymphoblastic leukemia, [11] [12] [13] although several lines of evidence have indicated that SCF influences the development of T and B cells. Mature human peripheral blood lymphocytes express little or no c-kit receptors. 14 In combination with IL-7, SCF was found to be a potent stimulus at early stages of T and B lymphoid development. 7, [15] [16] [17] [18] [19] [20] [21] [22] In mice, T cell proliferation occurred in a population of IL2R
− /CD3 − thymocytes by the combination of IL-7 and SCF. 20 A high level of c-kit expression defines pro-T cells which have not yet rearranged their TCR genes. 23 The proliferation of CD4loCD3 − CD8
− /c-kit
+ thymocytes was completely inhibited in the presence of antic-kit, which indicated an important role for c-kit/SCF interactions during early thymocyte development. 19 C-kit + cells derived from bone marrow differentiated into CD4CD8 double-positive cells, and did so approximately 4 days after c-kit + cells derived from thymus did. In the same study, anti-c-kit antibody blocked T cell generation of c-kit + bone marrow cells, but not of c-kit + thymus cells. 22 The growth conditions of T cell lymphoma or leukemia and their dependence on growth factors are of interest, because cytokines are being added to chemotherapy protocols for treatment of patients with these conditions. The cytokine SCF was tested in phase I clinical trials as an adjunct in the therapy of malignant disease. [24] [25] [26] [27] [28] Because of its stimulatory effects on early stem cells, SCF may become a candidate to support not only granulopoiesis, but also thrombopoiesis in the setting of high-dose chemotherapy and may gain significance in bone marrow transplantation like other widely used cytokines. 29, 30 SCF appears to be a potent mobilizer of peripheral blood stem cells (PBSCs), [31] [32] [33] [34] especially in conjunction with G-CSF. 6, 29, 35 Little is known about a direct stimulatory or inhibitory effect of SCF on childhood malignant T-lymphoblastic cells, although the expression of c-kit in T-lymphoblastic cells has been described previously. [36] [37] [38] [39] The finding that c-kit is involved in the growth regulation of thymocytes makes this receptor a candidate for involvement in the growth and development of T-lineage leukemia and lymphoma cells. Because of the potential clinical use of SCF, we examined the expression and regulation of c-kit receptor on pediatric malignant T-lymphoblastic cells and the direct effect of SCF on these cells.
Materials and methods

Cell lines and fresh lymphoblastic cells
The human T-lymphoblastic cell lines MOLT-3, MOLT-4, Jurkat, CCRF-HSB-2 and CCRF-CEM were obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA) and the cell lines MOLT-16 and SUP-T1 40 from the German Collection of Microorganisms and Cells (DSMZ, Braunschweig, Germany).
Fresh lymphoblastic cells from 21 patients were isolated by density gradient centrifugation (Ficoll-Paque; Pharmacia, Uppsala, Sweden), washed, and stored in liquid nitrogen with medium containing 10% dimethylsulfoxide (DMSO) and 20% fetal calf serum (FCS) until use. Thirteen of the 21 freshly isolated tumor cell preparations were obtained from pleural effusion, five from tumor or lymph node, and one each from peripheral blood and bone marrow (not expressing the CD117 antigen). The age at diagnosis ranged from 3 to 15 years. Four of the 21 patients were female and 17 were male.
After thawing, the cells were washed, resuspended in medium and cultured at 37°C for 1 day. Two of the fresh T-ALL cell preparations isolated from peripheral blood could be cultured over a time period of more than 6 months and were termed MHH-TALL-1 (patient 17: CD3 ). These cells were maintained at 37°C in humidified 5% CO 2 with weekly replacement of half of the medium. All cell lines were cultured in medium consisting of RPMI 1640 (Gibco BRL, Eggenstein, Germany) containing 10% FCS, and 0.25 g/ml antibiotic-antimycotic solution (Sigma, Deisenhofen, Germany). FCS was tested to support optimal growth of lymphoid cell lines. The megakaryoblastic cell line MO7e 41 was used as a positive control for c-kit expression. 3 
H-thymidine incorporation assays
The mitogenic activity of rhSCF was determined under serumfree conditions in a 3 H-thymidine incorporation assay as described elsewhere. 42 Significance of stimulation was analyzed by the paired Student's test by comparing the treated vs the untreated cells.
MTS metabolism assay
T-ALL and T-NHL cells were washed twice with serum-free medium containing RPMI 1640 supplemented with Iscove's supplement (Gibco BRL) and insulin-transferrin-sodium selenite supplement (Boehringer, Mannheim, Germany) to a final concentration of 20 g/ml soy bean lipids, 1 mg/ml bovine serum albumin fraction V, 21 g/ml transferrin, 1 g/ml insulin, 1 ng/ml sodium selenite. Cells were then plated in 96-well flat-bottom microtiter plates at 5 × 10 4 cells/ml in 200 l serum-free medium per well containing various concentrations (0, 50, 500 ng/ml) of rhSCF and 1 l phenazine methosulfate (PMS) and 20 l Owen's reagent (MTS) (Promega Celltiter AQ, Madison, WI, USA). The absorbance of the formazan at 490 nm was measured using an ELISA plate reader immediately after assay preparation. The plates were then incubated at 37°C and further color development was determined during the following days. Significance of stimulation was tested by the paired Student's test by comparing the treated vs the untreated cells.
Stimulation of T-ALL and T-NHL cells
To assess induced expression of c-kit and to demonstrate ckit regulation, the appropriate cytokine or reagent was added to the cells (5 × 10 5 cells/ml) in 25 cm 2 tissue culture flasks (Becton Dickinson, Meylan, France) containing 10 ml of culture medium with 10% FCS. The cells were cultured at 37°C in humidified CO 2 . The final concentrations of the cytokines or reagents and their suppliers were 100 ng/ml rhSCF (Amgen, Thousand Oaks, CA, USA), 20 ng/ml PMA (Sigma, St Louis, MO, USA), 100 ng/ml A 23187 (Sigma), 10 ng/ml TGF-␤ (Amgen), 1 ng/ml IL-1␤ (Amgen), 10 ng/ml IL-2 (Cetus, Emeryville, CA, USA), 10 ng/ml IL-7 (Promega), 5 ng/ml TNF-␣ (Knoll, Ludwigshafen, Germany).
Labeling of SCF and chemical crosslinking with digoxigenin-rhSCF (Dig-rhSCF)
One milliliter rhSCF (2.2 mg/ml) in buffer pH 8.5 was labeled by incubation at room temperature for 2 h with digoxigenin-3-0-methyl-carbonyl-⑀-aminocapronsäure-N-hydroxy-succinimidester (Dig) (Boehringer Mannheim) dissolved in 150 l ethanol as described elsewhere. 43 Free Dig was removed by a desalting column (Sephadex G-25). MO7e and MHH-TALL-1 cells, 5 × 10 6 cells in 100 l, were incubated with 15 l (0.13 mg/ml) Dig-rhSCF for 1 h on ice in the presence or absence of a 100-fold excess of unlabeled rhSCF. Cells were washed two times to remove unbound SCF. Subsequently, the cells were treated with 0.5 mmol/l of the bifunctional crosslinker disuccinimidylsuberate (DSS). The cells were lysed and the soluble proteins were denatured and separated in a 7.5% sodium dodecyl sulfate-polyacrylamide gel (SDS-PAGE). The gel was blotted on to a nylon membrane and DIGrh-SCF/c-kit complexes were detected using anti-Dig-AP-conjugated antibodies and the chemiluminescent substrate AMPPD. Membranes were exposed to Cronex DDS 100 autoradiography films (Sterling, Newark, DE, USA).
Flow cytometry (FCM)
Fc receptors were blocked by human IgG (Gammagard; Baxter, Unterschleissheim, Germany). Cell samples were incubated for 20 min on ice with saturating amounts of monoclonal antibody (MoAb) in PBS, 0.5% BSA, 0.1% sodium azide and were then washed twice in PBS, 0.1% BSA, 0.1% sodium azide. The MoAbs reacted with fluorescein isothiocyanate (FITC)-conjugated F(abЈ) 2 rabbit anti-mouse immunoglobulins (Dako, Hamburg, Germany) or by phycoerythrin (PE)-conjugated F(abЈ) 2 goat anti-mouse fragments (Dako) used as a second-step reagent. In addition, freshly isolated cells identified to express high amounts of c-kit were analyzed by double immunofluorescence. In this procedure, cells were stained by antibodies against CD117, CD10 or CD34 which were then detected by PE-conjugated F(abЈ) 2 fragments. An excess of irrelevant mouse Ig was used to block free antigen binding sites on the anti-mouse Ig-PE. Fc receptors were blocked by human IgG (Gammagard; Baxter). All samples were analyzed using a FACScan flow cytometer (Becton Dickinson, San Jose, CA, USA). Anti-CD117 (c-kit) MoAbs, supernatant from clone 57A5D8B1, were kindly provided by Dr H-J Bü hring (Tü bingen, Germany). The other MoAbs were from different sources: anti-CD3 (UCHT1) FITC-conjugated (DAKO), anti-CD4 (Leu-3A), anti-CD8 (Leu-2A), anti-CD10 (anti-cALLA) (Becton Dickinson), anti-CD19 (Leu-12) FITCconjugated (Becton Dickinson) and CD34 (anti-HPCA-2) (Becton Dickinson).
Results of FCM are given as mean ratio, calculated as the mean relative immunofluorescence using the specific antibody, divided by the mean relative immunofluorescence obtained with an irrelevant, isotype matched control antibody.
Results
C-kit receptor expression and its regulation on T-ALL and T-NHL cells
C-kit receptors were expressed on three out of seven T-lymphoblastic cell lines (Molt-4, SUPT-1 and CCRF-HSB-2; Table  1 ) and on nine of 21 freshly isolated T-lymphoblastic cells derived from children with T cell leukemia and lymphoma (Table 1 , and Figures 1 and 2 ). In addition, c-kit protein was upregulated within 48 h after addition of serum-containing medium to the freshly isolated T-NHL cells from patient 6 ( Figure 2 ) and to the 1-2 month culture cells from patient 4 (MHH-TALL-2; Figure 3 ). Freshly thawed and cultured cells, which were maintained in serum-free medium, or were maintained in serum-containing medium but not given fresh medium for at least 5 days, expressed c-kit protein only weakly or not at all. A significant c-kit expression was induced 20 h after addition of fresh medium (Figure 3 ). After that timepoint, c-kit expression again declined until fresh medium was added. Since upregulation of c-kit by the addition of serumcontaining medium was observed in cell culture, we asked Table 1 Expression of CD3, CD10, CD34, CD117 on freshly isolated malignant T-lymphoblastic cells and malignant T-lymphoblastic cell lines
Freshly isolated
Mean whether other cytokines or signals were also able to upregulate c-kit expression. We treated the cells with cytokines likely to be present in vivo and with second messenger reagents simulating other cytokine and microenvironmental influences. Upregulation of c-kit (CD117) expression by serum containing medium or by calcium ionophore in T-NHL cells from patient 6. Cells were thawed and analyzed by FCM directly (left), after 48 h in culture (middle) and after 48 h in the presence of A23187 (right) (treatment of the cells with A23187 caused cell death). Cells were stained with a mouse anti-CD117 antibody that was detected with PE-conjugated F(abЈ) 2 fragments and counterstained with a FITC-conjugated monoclonal anti-CD3 antibody.
Figure 3
Time course of c-kit induction on MHH-TALL-2 cells. MHH-TALL-2 cells were maintained in serum-containing medium for 5 days without passaging and were diluted with one volume of fresh medium and immunofluorescence of CD117, CD3 and CD10 was measured after culture periods of 6, 20 and 48 h. The values are given as mean ratios of immunofluorescence.
shown). Also to detect influences other than antigen expression, we estimated size of the cells by flow cytometric methods. Figure 4 summarizes the effects of the reagents on antigen expression after 48 h, and Figure 5 gives the time course of the expression. These results could be confirmed during repeated experiments and the same regulation occurred in the cell line MO7e with SCF, PMA and A23187 (data not shown).
Upregulation of c-kit was not seen after addition of its own ligand, SCF, which persisted for up to 48 h ( Figure 5 ). PMA also downregulated c-kit expression and had the same downregulatory effect on CD3, but upregulated CD10. The calcium ionophore A23187 and the cytokine TNF-␣ both markedly upregulated c-kit expression, and had different regulatory effects on the CD3 and CD10 antigens used as controls. The upregulation of c-kit by these two reagents was not complete at 20 h but continued to increase up to the 48 h investigated. Upregulation of c-kit by A23187 but not by TNF-␣ was also seen in the MO7e cells used as controls (data not shown). IL-
Figure 4
Expression of CD117, CD3 and change in and cell size of MHH-TALL-2 after treatment with various reagents and cytokines. Cells were cultured for 48 h in medium containing the indicated cytokines or reagents and mean ratios of fluorescence were determined by FCM. The values for antigen expression were plotted as the percentage increase or decrease of mean ratio in the presence or absence of the respective reagent. Untreated cells were set to 100%.
2 had only minor influence on the expression of the c-kit, CD3 and CD10 antigens. The cytokines IL-7 and IL1-␤ had little influence on the T-lymphoblastic cells in our experiments. 
Figure 6
Chemical crosslinking of Dig-labeled SCF to c-kit receptors on MHH-TALL-1 cells. Dig-labeled SCF was crosslinked to T-ALL cells and the cellular proteins were separated after lysis by SDSpolyacrylamide gel electrophoreses and blotted on to a nylon membrane. The complex consisting of Dig-labeled SCF and c-kit receptors was detected by chemiluminescence (arrow). 
Downmodulation of c-kit receptors by SCF on T-lymphoblastic cells
In all except one of the c-kit-positive T-lymphoblastic cells, preincubation with rhSCF for 3-6 h before FCM analysis resulted in a reduced capacity to bind anti-c-kit antibodies (Table 2) . (Different levels of c-kit expression compared to levels given in Table 1 are due to different culture conditions.) Time course experiments in SUP-T1 cells showed that about half of the c-kit receptors are already downmodulated after an incubation period of 10 min at 37°C in the presence of rhSCF. At 4°C, no downmodulation of c-kit receptors occurred in SUP-T1 cells during 10 min incubation in the presence of rhSCF (data not shown). These experiments indicated that competition between ligand and antibody was not the reason for decreased receptor detection by antibody.
Determination of the molecular weight of the c-kit receptor on MHH-TALL-1 cells
To demonstrate SCF binding and to determine the molecular weight of the SCF receptor on a T-ALL cell line we crosslinked digoxigenin-labeled rhSCF to the cell surface of the MHH-TALL-1 and to the positive control MO7e cell line, respectively. A cytokine-receptor complex of 165-170 kDa, corresponding to the expected molecular weight of the c-kit receptor of approximately 150 kDa was found in MHH-TALL-1 cells and in MO7e cells. Specific displacement of labeled SCF from c-kit receptor could be demonstrated by addition of a 100-fold molar excess of unlabeled SCF ( Figure 6 ). C-kit receptors could not be demonstrated on freshly thawed MHH-TALL-1 cells.
Mitogenic activity of rhSCF on freshly isolated T-lymphoblastic cells and cell lines
The mitogenic activity of rhSCF was tested by MTS metabolism and 3 H-thymidine incorporation on three c-kit-positive cell lines, and on seven c-kit-positive fresh biopsy cell preparations. MO7e megakaryoblastic cells again served as positive controls. A significant dose-dependent proliferative response to rhSCF was detected in three out of 21 freshly isolated T-lymphoblastic cell preparations. Positive were patients 4 (whose cells later became the MHH-TALL-2 cell line), 5 and 17 (later the MHH-TALL-1 cell line) and the MO7e cells (Figures 7 and 8) . Dose-dependent proliferation is shown in the range of 1-50 ng/ml rhSCF for patient 17 (fresh cells) (Figure 8) . However, all cells tested were already maximally stimulated by 50 ng/ml rhSCF and no dose-response occurred despite a 10-fold increase in SCF concentration. One cell line (MHH-TALL-2) was tested in a 3 H-thymidine proliferation assay side by side with the cryopreserved fresh tumor cells (patient 4) from which they were derived (Figure 8 ). The proliferative response to SCF was similar in both preparations, indicating that the SCF responsiveness was not merely acquired or lost during prolonged tissue culture. In addition, the three adult T-lymphoblastic cell lines Hut78, Hut102 and MT-1 were investigated. None of these cell lines proliferated in response to SCF and only MT-1 showed c-kit expression and c-kit downmodulation upon treatment with rhSCF (data not shown).
Discussion
The aim of this study was to determine the role of c-kit in childhood T-NHL and T-ALL cells. Because of the potential clinical use of SCF in patients undergoing autologous stem cell mobilization, [24] [25] [26] [27] [28] [29] we investigated c-kit expression in childhood T-lymphoblastic cell lines and in freshly isolated biopsy tumor cells. We could demonstrate c-kit protein expression by flow cytometry or receptor crosslinking on freshly isolated blast cells from nine of 21 patients with T-ALL or T-NHL. In addition, three of seven malignant childhood Tlymphoblastic cell lines expressed the c-kit protein.
In contrast to most cases of myeloid leukemia, little or no expression of c-kit had been observed in human leukemia cell lines of lymphoid lineage [9] [10] [11] and in blast cells of acute lymphoblastic leukemic so far. [11] [12] [13] However, an IL-2-dependent T-lymphoblastic leukemia cell line that was stimulated to secrete GM-CSF by SCF, 37 and a case of T-ALL blast cells producing small amounts of c-kit mRNA have been described. 36 More recently, our results 38, 44 have been confirmed by Kees and Ashman 45 who found c-kit expression in three of five T-ALL cell lines, and SCF had an synergistic proliferative effect with IL-2 on one of these cells. Sperling et al 39 discovered CD 117 in a small proportion of T-lineage ALL (9%) and Ichinohasama et al 46 found a c-kit expressing T-lymphoblastic lymphoma. C-kit expression appears to be a rare event in lymphoblastic leukemia of B-lineage, however. 39 Valverde et al, 47 found only one of 23 ALL cells of different types positive for c-kit expression and Morita et al 48 found no c-kit expression in 44 lymphoid blast preparations from pediatric leukemia patients and 20 cell lines of erythroid and lymphoid lineages. Whether c-kit is biologically active by transducing a growth signal in the T-lymphoblastic cells was not studied by these investigators.
With our experiments we could demonstrate downmodulation of the receptor in the presence of rhSCF in all except one of the c-kit-positive T-lymphoblastic cells tested. Only one of the permanent cell lines, but three of nine freshly isolated blast cell preparations proliferated in the presence of SCF.
That most investigators did not detect expression of c-kit in malignant cells of the lymphoid lineage may have been due to the fact that the cells were examined in a resting metabolic state, eg directly after thawing of tissue material for the initial diagnostic workup. We made similar observations, but cryopreservation might have damaged the cell surface proteins, have changed the protein conformation or have resulted in shedding of the receptors, making impossible to detect the receptor by flow cytometry. However, since upregulation of c-kit occurred after adding fresh medium to the cells, changes in their metabolic state seem to be the more likely reason for this observation. Metabolic state or cell cycle activity were previously reported to have marked effects on c-kit expression. C-kit expression was upregulated by the c-myb transcription factor, which plays an important role for progression through the cell cycle. Expression of c-kit was essentially abrogated by arresting the growth of human bone marrow mononuclear cells or by inhibiting myb gene function. 49 Consistent with these results, we found that c-kit protein was only minimally expressed in freshly thawed biopsy T-ALL and T-NHL cells, but was upregulated within 48 h after the addition of fresh medium.
Leukemic cells in vivo are exposed to many factors and cytokines that could theoretically induce or influence c-kit receptor expression. Our results, using the T-lymphoblastic cell line MHH-TALL-2, showed that the most potent regulators in vitro were A23187 and TNF-␣ as upregulators, and PMA and SCF as downregulators of c-kit expression. In our study, TGF-␤ led to an upregulation in T-lymphoblastic cells but to a downregulation in MO7e cells, used as a control. TGF-␤ treatment of progenitor cell lines and murine primary progenitor cells, which constitutively express functional cell-surface c-kit, resulted in downregulation of cell-surface c-kit
Figure 7
Proliferative effect of rhSCF on fresh cells and cell lines from patients with T-ALL and T-NHL (MTS reduction) (data from all other negative cells and cell lines not shown). T-lymphoblastic cells were washed, resuspended in serum-free medium and added to the wells of a 96-well plate containing various concentrations of rhSCF (0 = ć, 50 = b, 500 = ng/ml) and the combined MTS/PMS solution. Plates were incubated at 37°C and absorbance at 490 nm was recorded using an ELISA plate reader at the indicated times. Absorbance of MTS/PMS in the absence of cells was subtracted at each timepoint. Data are given as means of triplicates with standard deviation. Significance were tested with Student's t-test for treated vs untreated cells (*P Ͻ 0.001).
expression by a decrease of c-kit message stability starting after 2 h of TGF-␤ treatment. 50 PMA treatment in our study led to a downregulation of c-kit on the protein level. The concomitant upregulation of the CD10 antigen suggested that downregulation of c-kit was not due to toxic effects of the PMA treatment. The T cell and thymocyte growth factors IL-2 or IL-7 did not significantly influence the expression of ckit. Receptor downmodulation by SCF was seen in eight of our nine c-kit-positive T-lymphoblastic cell preparations resembling the observation of Pietsch et al 41 in AML cells. The mechanism of downmodulation may be the one described by Yee et al 51 in mast cells, where SCF was rapidly internalized and receptor degradation was accelerated after binding of SCF to its receptor. Our results show that c-kit expression can be influenced by cytokines and other factors. Therefore, c-kit expression in vivo might be different to the in vitro situation. This has to be considered when c-kit expression is judged by in vitro experiments, especially in the absence of those cytokines.
In addition, our results show that c-kit expression is not restricted to immature, CD34
+ bone marrow precursors cells 52 and myeloid leukemic cells, 13 although c-kit expression is certainly much more common in normal early hematopoietic progenitor cells and in the myelodysplastic and myeloproliferative disorders 53 than in lymphoid cells. We conclude that: (1) c-kit can be expressed on malignant T-lymphoblastic cells derived from children with T cell lymphoma or leukemia; (2) that the characteristics of the c-kit protein are similar to the ones described for other cell types. These characteristics include molecular weight, specific regulation by different reagents and cytokines, and susceptibility to downmodulation by the receptor's own ligand SCF; (3) ckit is biologically active by transducing a growth signal in some of the T-lymphoblastic cells; and (4) that c-kit expression may not be evident on freshly thawed malignant cells which are usually used for diagnostic immunophenotyping, but may only become apparent after brief periods of culture or after stimulation with calcium ionophore.
Mobilization and peripheral stem cell expansion in the presence of SCF is entering clinical practice. The fact that ckit expression may not be apparent on fresh malignant T cells at the initial diagnostic workup, and the possibility of a proliferative effect of SCF on these cells have to be especially considered. Ex vivo expansion of bone marrow cells by SCF might also lead to an expansion of contaminating malignant cells. When SCF is used as an adjunct to chemotherapy proto- cols, a direct negative influence of treatment with SCF on children suffering from T-lymphoblastic malignancies appears to be a possibility. Whether SCF has a direct influence on the growth of leukemia or lymphoma cells in vivo resulting in a clinically relevant change in the outcome of patients can only be answered by clinical studies.
